USPTO serial 97815166
ENVISIA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 13, 2026
- Examiner
- LEVINE,HOWARD B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ENVISIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
South San Francisco, CA
South San Francisco, CA
South San Francisco, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rosaleen H. Chou
Rosaleen H. Chou KNOBBE, MARTENS, OLSON & BEAR, LLP2040 MAIN STREET, 14TH FLOORIRVINE, CA 92614United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for scientific or research use; Diagnostic kits and test kits primarily composed of reagents for determination of genomic and transcriptomic information for scientific or research purposes; Testing kits comprised primarily of preparations, reagents, test strips, collection tubes, buffers, tube holders, transport bags and assays for use in scientific or research in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Biological agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for scientific and research use; Diagnostic reagents and preparations, other than for medical and veterinary use; Kits comprised primarily of biological reagents and comprised secondarily of a protocol in the form of printed instructions for use thereof for scientific and research purposes; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for scientific or research purposes; Reagents and molecule or cell markers for scientific or research purposes | ACTIVE | May 17, 2018 |
| 005 | Kits for in vitro diagnostic testing for pulmonary diseases and conditions; Reagents for medical use; Molecular diagnostic assays for testing of bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Medical preparations used to diagnose bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Diagnostic agents, preparations and substances for medical purposes; Diagnostic test kits consisting primarily of reagents for use in testing bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Medical diagnostic test kits consisting primarily of reagents for detecting pathogens; Clinical medical diagnostic reagents, medical diagnostic assays for medical and diagnostic purposes for testing genetic material; Clinical, genetic and specialized medical diagnostic test kits comprised primarily of buffers, collection tubes, tube holders, transport bags, shipping containers, and instruction sheets for use in scientific and clinical diagnostic equipment used to detect disease, cancer, genetics, and pathogens; Chemicals, assays, reagents and kits consisting primarily of chemicals, assays, and reagents for medical testing and diagnostic purposes in the fields of genomics, diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Medical diagnostic reagents, and kits comprised of medical diagnostic reagents, collection tubes, buffers, tube holders, transport bags, and instruction sheets, for diagnostic testing in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Medical diagnostic testing kits comprised primarily of reagents and assays for use in diagnostics and diagnostic testing in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for medical diagnostic use | ACTIVE | May 17, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 13, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 13, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 25, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 25, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 19, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 28, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 27, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 27, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 27, 2025 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jun 25, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Dec 27, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jun 28, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 28, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 28, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 29, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 22, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Feb 22, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Nov 29, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 29, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 29, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 29, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 19, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 3, 2023 | NWAP | NEW APPLICATION ENTERED | — |